DelveInsight's 'Follicular Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline ...

Our bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called ...

Our bodies divest themselves of 60 billion cells every day through a natural process of cell culling and turnover called apoptosis.

Flipping the cancer script One of these proteins, BCL6, when mutated, drives the blood cancer known as diffuse large cell B-cell lymphoma. This kind of cancer-driving protein is also referred to as an ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a higher risk version ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

This is compared to 83% ... Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non ...